Talking on wired landline phones. Magazines. TV was the only doomscroll-y device. Newspapers. Deviceless Sundays. Making friendship bracelets. Family shares one computer. CDs. Burning CDs for friends. First digital camera (SONY cybershot). Yahoo. Knowing all your tier 1 people’s phone numbers by heart.

I say this completely respectfully, your concert memory probably sucks because you are watching through your phone half the time at the show. Give it a shot, let yourself completely connect to the music deviceless. It’s a one of kind experience I promise.

deviceless ping received and confirmed. Occam's razor says is real, not "serious misalignment"... 😜

I drew earlier when I was deviceless who wanna see (mandatory)

I'm going to China next week, and honestly, looking forward to being deviceless and offline. I got some paperback books and sewing; it's gonna be like mental vacation. 🥳

This is easy, you have to do it deviceless next time

When I was a kid, when I got angry I usually smashed my tablet, so idk maybe my brother pissed me off, I smashed my angelnovo tablet that I got from my last holiday in ny, my mother got a new one the next day, after a month I did it again😭 I was deviceless for a year😂😂😂

FedEx ur phones home and always fly deviceless or travel with a burner. Be wiser next time. This is Nazi germany 1941 not the U.S. anymore. Wake up kids

FedEx your phones home and fly deviceless.

Ok. My friend has a S21FE which he had bought in 2023. It now has a green line. Suppose his display is replaced by the company free of cost. Acc to u, he should sell his device and be deviceless. Or exchange for 6k. So, should he buy a 6k worth device? (1/2)

If you like dinner parties, check out our deviceless dinner club: tally.so/r/VL02Ya

GUYS OOMFS IM BACK IM CRINE I ALMOST WENT INSANE I MISS YOU ALL basically my laptop ALSO stopped working so i was deviceless (im using my sisters ipad rn) I MISS YALL SM.

Health system leaders have asked me how Digital Health can help them navigate the CMS TEAM bundled payment model that is now REAL. Here are the 6 strategies I tell them: First though, you need the right underlying Digital Health platform. The following is based on our own experience with @SeamlessMD for digital care journeys: a platform that navigates patients with automated reminders, education and symptom monitoring across the episode of care - fully integrated with the EHR and customized for each surgical procedure (e.g. hip, knee, CABG, etc.). With that out of the way, here are the 6 strategies I tell health systems on using digital care journeys to succeed: 1/ Standardize care pathways Clinical variation creates unpredictable costs. Digitize “gold standard” pathways (e.g. ERAS) into automated, bite-sized steps delivered to patients. By ensuring every patient receives the same evidence-based preparation and recovery protocols, outcomes become more predictable and less expensive. 2/ Improve confidence for earlier discharge and lower length of stay Shortening LOS by even half a day significantly impacts performance. Digital platforms reinforce recovery goals - like early mobilization - in real-time. Patients who feel "digitally supported" at-home are more confident being discharged 0.5 to 1 day earlier - and care teams feel more confident discharging them sooner too. 3/ Transition more patients directly home Post-acute care represents 15% - 25% of episode costs, driven by the costs of SNF/rehab. Digital care journeys act as a virtual safety net - by monitoring recovery data remotely, clinical teams can intervene early if "red flags" appear, making patients more willing to have a discharge to home. 4/ Use “deviceless” monitoring to prevent readmissions Many readmissions are caused by preventable, manageable issues such as dehydration or medication confusion. "Deviceless" remote monitoring (using simple app-based symptoms checks) are more cost-effective and scalable to thousands of patients than hardware-heavy remote patient monitoring. We’ve seen health systems use digital care journey monitoring to reduce readmissions by 45% to 89% for the very conditions affected by CMS TEAM - no device-heavy RPM kit required. 5/ Automate collection of PROMs The TEAM model requires capturing Patient-Reported Outcome Measures (PROMs). Manual collection via mail, in-person or phone is labor-intensive and leads to gaps in response rates. Digital care journeys automate these questionnaires by integrating them into the daily preparation and recovery journey, supporting higher high participation rates needed for CMS quality thresholds. 6/ Close the loop with primary care TEAM mandates referring patients back to primary care to ensure long-term accountability. Digital care journeys facilitate this by prompting patients to schedule and confirm follow-up appointments, reducing the fragmentation that leads to poor long-term outcomes. No, Digital Health won’t solve everything for the CMS TEAM model - but it can certainly be an enabler for many of the strategies needed to ensure safer, more cost-effective surgical care. If your health system wants a deeper dive into how these strategies work, feel free to give me a shout!

Deviceless.

CRISPR Therapeutics $CRSP Earnings Summary - February 12, 2026 Business Performance Analysis CRISPR Therapeutics' financial performance in 2025 reflects a pivotal year marked by the initial commercialization success of CASGEVY® and significant advancements across a broad and maturing gene-editing pipeline. The substantial increase in collaboration expense, net, from $10.4 million in Q4 2024 to $53.7 million in Q4 2025, and a rise in R&D expenses to $83.5 million in Q4 2025, underscore the company's strategic investment in pipeline development and its share of costs for CASGEVY under the Vertex collaboration. This aggressive investment, coupled with the absence of a comparable deferral in collaboration expenses seen in 2024, contributed to the increased net loss, even as CASGEVY began generating meaningful revenue. The CEO's commentary highlights continued execution across the portfolio, strengthening platform capabilities, and global uptake of CASGEVY as key drivers of progress. Key Financial Highlights Total Revenue (FY 2025): $3,510 million, primarily from collaboration and grant revenue. CASGEVY Revenue (FY 2025): $116 million, with $54 million generated in Q4 2025. Net Loss (Q4 2025): $130.6 million, compared to $37.3 million in Q4 2024. R&D Expenses (Q4 2025): $83.5 million, up from $71.7 million in Q4 2024, driven by increased licensing fees. Collaboration Expense, Net (Q4 2025): $53.7 million, significantly up from $10.4 million in Q4 2024 due to the absence of a deferral seen in the prior year. Cash Position (as of Dec 31, 2025): $1,975.8 million in cash, cash equivalents, and marketable securities, an increase from $1,903.8 million at year-end 2024, primarily from common share issuance and option exercises. Key Takeaways The most significant development is the successful initial commercialization and global uptake of CASGEVY®, the world's first CRISPR-based therapy, which generated $116 million in full-year 2025 revenue and saw 147 patients initiate treatment. This commercial momentum is further bolstered by positive pediatric data presented at ASH 2025, with global regulatory submissions for children aged 5-11 years expected to begin in the first half of 2026, supported by an FDA Commissioner's National Priority Voucher. Beyond CASGEVY, the company is advancing a diversified pipeline leveraging its proprietary LNP delivery platform for in vivo liver editing programs (CTX310, CTX321, CTX460, CTX340), progressing siRNA-based programs in collaboration with Sirius Therapeutics (CTX611), and expanding its allogeneic CAR-T cell therapy (zugo-cel) into multiple autoimmune and immuno-oncology indications. The advancement of CTX213, a deviceless beta cell replacement candidate for Type 1 diabetes, highlights the strategic expansion into regenerative medicine, demonstrating compelling preclinical efficacy. The company's wholly-owned GMP manufacturing facility in Framingham further strengthens its end-to-end production capabilities for cell therapy. Guidance CRISPR Therapeutics anticipates several key milestones and updates in 2026. Global regulatory submissions for CASGEVY in pediatric patients (5-11 years) with SCD or TDT are expected to commence in the first half of 2026. The company expects to provide updates on its in vivo liver editing programs, CTX310 and CTX321, in the second half of 2026. An update on the siRNA program CTX611 is also expected in the second half of 2026, with CRISPR Therapeutics leading global Phase 3 development. Updates for zugo-cel in both autoimmune disease and immuno-oncology are anticipated in the second half of 2026. Additionally, clinical trial initiations for CTX460 and CTX340 are expected in mid-2026 and the first half of 2026, respectively. The company also plans to provide additional updates on its regenerative medicine program, CTX213, as development progresses.

Apple, if we move to an age of no devices where anything can be used to display a screen, then there is a possibility that people will stop using iPhones. There is no innovation from Apple on deviceless displays.

i have no pictures of me from 2016 i was deviceless at the time

A deviceless future is near. Any device can dynamically become your device.

The most inspiring thing I read in Bitcoin each year is Ross Stevens’ annual Investor Letter. Was blessed to visit their office this past month and sit in one of these deviceless meetings.